"Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 1: "Goldilocks" Actions at Dopamine Receptors: (Brainstorms)

DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro

Vliet, B. J. V., Ronken, E., Tulp, M. T. M., Feenstra, R., Kruse, C. G., & Long, S. K. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80319-3 · Cited by 12

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,131

The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes

Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769

A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania

Keck, P. E., Marcus, R. N., Tourkodimitris, S., Ali, M. W., Liebeskind, A., Saha, A. R., Ingenito, G. G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

Marder, S. R., McQuade, R. D., Stock, E. G., Kaplita, S., Marcus, R. N., Safferman, A. Z., Saha, A. R., Ali, M. W., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467

Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability

DeLeon, A., Patel, N. C., & Crismon, M. L. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90066-5 · Cited by 364

Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?

Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311

Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings

Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299

Aripiprazole

Harrison, T. S., & Perry, C. M. (2004) · Drugs · doi:10.2165/00003495-200464150-00010 · Cited by 276

Pathophysiology and Treatment of Psychosis in Parkinson’s Disease

Zahodne, L. B., & Fernandez, H. H. (2008) · Drugs & Aging · doi:10.2165/00002512-200825080-00004 · Cited by 211

GPCR functional selectivity has therapeutic impact

Mailman, R. B. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.002 · Cited by 208

Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain

Li, Z., Ichikawa, J., Dai, J., & Meltzer, H. Y. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.04.028 · Cited by 203

Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics

Revel, F. G., Moreau, J., Gainetdinov, R. R., Ferragud, A., Velázquez-Sánchez, C., Sotnikova, T. D., Morairty, S. R., Harmeier, A., Zbinden, K. G., Norcross, R. D., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.014 · Cited by 195

Medication Development for Addictive Disorders: The State of the Science

Vocci, F. J., Acri, J. B., & Elkashef, A. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1432 · Cited by 192

Medications development: Successes and challenges

Vocci, F. J., & Ling, W. W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.010 · Cited by 161

Atypicality of Atypical Antipsychotics

Farah, A. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0602 · Cited by 132

Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity

Tuplin, E. W. N., & Holahan, M. R. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170413115754 · Cited by 131

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic

Keck, P. E., & McElroy, S. L. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.655 · Cited by 120

Aripiprazole in Schizophrenia With Cocaine Dependence

Beresford, T. P., Clapp, L., Martin, B., Wiberg, J. L., Alfers, J., & Beresford, H. F. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000169419.38899.5b · Cited by 119

A ‘Goldilocks’ hypothesis for dispersal of biological control agents

Heimpel, G. E., & Asplen, M. K. (2011) · BioControl · doi:10.1007/s10526-011-9381-7 · Cited by 117

Aripiprazole in schizophrenia and schizoaffective disorder: A review

Stip, É., & Tourjman, V. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.01.021 · Cited by 116

Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs

Boyd, K. N., & Mailman, R. B. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_3 · Cited by 109

A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy

Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90

Aripiprazole possibly worsens psychosis

Ramaswamy, S., Dewan, V. K., Marcil, W., Sattar, S. P., Praveen, F., & Petty, F. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200401000-00009 · Cited by 85

Clinical Effects and Adverse Reactions of Off-Label Use of Aripiprazole in Children and Adolescents with Developmental Disabilities

Valicenti-McDermott, M., & Demb, H. B. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.549 · Cited by 81

Prolactin awareness: An essential consideration for physical health in schizophrenia

Montejo, A. L. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.02.004 · Cited by 78

Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism

Naber, D., & Lambert, M. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.06.020 · Cited by 78

A safety evaluation of aripiprazole in the treatment of schizophrenia

Preda, A., & Shapiro, B. B. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1832990 · Cited by 77

The place of partial agonism in psychiatry: recent developments

Ohlsen, R. I., & Pilowsky, L. S. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105053308 · Cited by 77

Antipsychotic drug efficacy correlates with the modulation of D1 rather than D2 receptor-expressing striatal projection neurons

Yun, S., Yang, B., Anair, J. D., Martin, M. M., Fleps, S. W., Pamukcu, A., Yeh, N.-H., Contractor, A., Kennedy, A., & Parker, J. G. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01390-9 · Cited by 72

An Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression

Patkar, A. A., Peindl, K., Mago, R., Mannelli, P., & Masand, P. S. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0205 · Cited by 60

The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy

Costa-Dookhan, K. A., Agarwal, S. M., Chintoh, A. F., Tran, V., Stogios, N., Ebdrup, B. H., Sockalingam, S., Rajji, T. K., Remington, G. J., Siskind, D. J., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1698545 · Cited by 60

Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice

Bourin, M., Chenu, F., Prica, C., & Hascoët, M. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1583-7 · Cited by 59

Aripiprazole: pharmacology, efficacy, safety and tolerability

Kinghorn, W. A., & McEvoy, J. P. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.3.297 · Cited by 55

Aripiprazole and Atypical Neuroleptic Malignant Syndrome

Spalding, S. R., Alessi, N. E., & Radwan, K. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000142277.95052.94 · Cited by 53

Quetiapine for primary insomnia: Consider the risks

Modesto‐Lowe, V., Harabasz, A. K., & Walker, S. A. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20031 · Cited by 52

Biological Perspectives

Keltner, N. L., & Johnson, V. (2002) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2002.tb01566.x · Cited by 43

Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway

Ishii, D., Matsuzawa, D., Kanahara, N., Matsuda, S., Sutoh, C., Ohtsuka, H., Nakazawa, K., Kohno, M., Hashimoto, K., Iyo, M., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.01.010 · Cited by 41

Atypical Neuroleptic Malignant Syndrome or Serotonin Toxicity Associated with Atypical Antipsychotics?

Odagaki, Y. (2009) · Current Drug Safety · doi:10.2174/157488609787354387 · Cited by 41

Development and validation of a high-performance liquid chromatography method using diode array detection for the simultaneous quantification of aripiprazole and dehydro-aripiprazole in human plasma

Lancelin, F., DJEBRANI, K., Tabaouti, K., Kraoul, L., Brovedani, S., Paubel, P., & Piketty, M. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.02.026 · Cited by 39

Role of Dopamine 2 Receptor in Impaired Drug-Cue Extinction in Adolescent Rats

Zbukvic, I., Ganella, D. E., Perry, C. J., Madsen, H. B., Bye, C. R., Lawrence, A. J., & Kim, J. H. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw051 · Cited by 38

The Role of the Dopamine D2 Receptor in Form-Deprivation Myopia in Mice: Studies With Full and Partial D2 Receptor Agonists and Knockouts

Huang, F., Wang, Q., Yan, T., Tang, J., Hou, X., Shu, Z., Wan, F., Yang, Y., Qu, J., & Zhou, X. (2020) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.61.6.47 · Cited by 37

The 5-HT2 Receptor Profiles of Antipsychotics in the Pathogenesis of Obsessive-Compulsive Symptoms in Schizophrenia

Kim, S., Shin, I., Kim, J., Youn, T., Yang, S., Hwang, M. Y., & Yoon, J. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318184fafd · Cited by 36

Antipsychotic drug—aripiprazole against schizophrenia, its therapeutic and metabolic effects associated with gene polymorphisms

Stelmach, A., Guzek, K., Rożnowska, A., Najbar, I., & Sadakierska−Chudy, A. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00440-6 · Cited by 32

Aripiprazole: A clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness

Katzman, M. A. (2011) · Journal of Affective Disorders · doi:10.1016/s0165-0327(11)70004-0 · Cited by 33

Patterns of Antipsychotic Prescription to Patients with Schizophrenia in Korea: Results from the Health Insurance Review & Assessment Service-National Patient Sample

Park, S., Lee, M.-S., Kang, S., & Lee, S. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.5.719 · Cited by 31

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder

Taylor, D. M., & Bishara, D. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s5742 · Cited by 30

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Irritability in Autistic Children

Kirino, E. (2014) · Clinical Medicine Insights Pediatrics · doi:10.4137/cmped.s8304 · Cited by 29

The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice

Almeida‐Santos, A. F., Gobira, P. H., Souza, D. P., Ferreira, R. C. M., Romero, T. R. L., Duarte, I. D. G., de Aguiar, D. C., & Moreira, F. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.004 · Cited by 29

Pharmacological Strategies for Bipolar Disorders in Acute Phases and Chronic Management with a Special Focus on Lithium, Valproic Acid, and Atypical Antipsychotics

Carli, M., Weiss, F., Grenno, G., Ponzini, S., Kolachalam, S., Vaglini, F., Viaggi, C., Pardini, C., Tidona, S., Longoni, B., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230224102318 · Cited by 33

Two Cases of Hypersexuality Probably Associated with Aripiprazole

Cheon, E., Koo, B., Seo, S. S., & Lee, J.-Y. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.2.200 · Cited by 27

Partial agonists in schizophrenia – why some work and others do not: insights from preclinical animal models

Natesan, S., Reckless, G. E., Barlow, K. B. L., Nóbrega, J. N., & Kapur, S. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001343 · Cited by 27

Dopaminergic hypofunctions and prepulse inhibition deficits in mice lacking midkine

Ohgake, S., Shimizu, E., Hashimoto, K., Okamura, N., Koike, K., Koizumi, H., Fujisaki, M., Kanahara, N., Matsuda, S., Sutoh, C., et al. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.02.005 · Cited by 26

Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns

Apiquián, R., Fresán, A., de la Fuente‐Sandoval, C., Ulloa, R. E., & Nicolini, H. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-12 · Cited by 25

Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?

Albers, L. J., Musenga, A., & Raggi, M. A. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.61 · Cited by 24

Dysfunction of Serotonergic and Dopaminergic Neuronal Systems in the Antidepressant-Resistant Impairment of Social Behaviors Induced by Social Defeat Stress Exposure as Juveniles

Hasegawa, S., Miyake, Y., Yoshimi, A., Mouri, A., Hida, H., Yamada, K., Ozaki, N., Nabeshima, T., & Noda, Y. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy038 · Cited by 26

Collateral efficacy as a pharmacological problem applied to new drug discovery

Kenakin, T. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.7.635 · Cited by 25

Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation

Omori, Y., Kanbayashi, T., Sagawa, Y., Imanishi, A., Tsutsui, K., Takahashi, Y., Takeshima, M., Takaki, M., Nishino, S., & Shimizu, T. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s158865 · Cited by 24

Aripiprazole-induced oculogyric crisis (acute dystonia)

Bhachech, J. T. (2012) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.99446 · Cited by 23

Treatment for mood and anxiety disorders: Quetiapine and aripiprazole

Sajatovic, M. (2003) · Current Psychiatry Reports · doi:10.1007/s11920-003-0062-9 · Cited by 23

Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment

Jannini, T. B., Sansone, A., Rossi, R., Lorenzo, G. D., Toscano, M., Siracusano, A., & Jannini, E. A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2071124 · Cited by 21

Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports

Lataster, J., Myin‐Germeys, I., Wichers, M., Delespaul, P., van Os, J., & Bak, M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311419552 · Cited by 21

Antipsychotic treatment in schizophrenia: atypical options and NICE guidance

Mortimer, A. M. (2003) · European Psychiatry · doi:10.1016/s0924-9338(03)00060-9 · Cited by 20

Seventy Years of Antipsychotic Development: A Critical Review

Shad, M. U. (2023) · Biomedicines · doi:10.3390/biomedicines11010130 · Cited by 19

Selective Actions on Sleep or Anxiety by Exploiting GABA-A/Benzodiazepine Receptor Subtypes

Stahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0301 · Cited by 19

Do Dopamine Partial Agonists Have Partial Efficacy as Antipsychotics?

Stahl, S. M. (2008) · CNS Spectrums · doi:10.1017/s1092852900016382 · Cited by 18

Agitation Associated with Aripiprazole Initiation

Lea, J. W., Stoner, S. C., & LaFollette, J. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.9.1339 · Cited by 18

Drug-Induced Movement Disorders

Friedman, J. H., & Fernandez, H. H. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50063-3 · Cited by 18

Differentiating the third generation of antipsychotics: a focus on lumateperone’s similarities and differences

Maldonado, G. M. M., & Schwartz, T. L. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000510 · Cited by 17

The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?

Lippi, M., Fanelli, G., Fabbri, C., Ronchi, D. D., & Serretti, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000417 · Cited by 20

Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats

Li, S., Zou, Y., Liu, L.-J., Wu, P., & Lü, L. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.01.014 · Cited by 17

Practical guidance for prescribing with aripiprazole in bipolar disorder

Fagiolini, A. M. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802341426 · Cited by 16

The effect of acute aripiprazole treatment on chemically and electrically induced seizures in mice: The role of nitric oxide

Shafaroodi, H., Oveisi, S., Hosseini, M., Niknahad, H., & Moezi, L. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.05.018 · Cited by 16

Adjunctive brexpiprazole for the treatment of major depressive disorder

Beyer, J. L., & Weisler, R. H. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1254188 · Cited by 16

Systemic review of aripiprazole for the treatment of children and adolescents with tic disorders

Ghanizadeh, A. J. (2012) · Neurosciences · doi:10.17712/1658-3183.1947 · Cited by 15

ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders

Noel, J. M. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060343 · Cited by 15

Novel antipsychotics in schizophrenia

Mortimer, A. M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.315 · Cited by 15

Aripiprazole: A dopamine modulator that mimics methylphenidate in producing faster antidepressant effects

Chen, T., & Tzeng, N. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.05.009 · Cited by 14

The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression

Waters, N., Pontén, H., Edling, M., Svanberg, B., Klamer, D., & Waters, N. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1231-1 · Cited by 13

Aripiprazole-imprinted poly(hydroxyethyl methacrylate) cryogel patches for enhanced drug release

Çalışır, M., Erkek, M., Deni̇zli̇, A., & Bereli, N. (2025) · Polymer Bulletin · doi:10.1007/s00289-025-05831-2 · Cited by 12

Aripiprazole for the treatment of bipolar disorder: a review of current evidence

Fagiolini, A. M., Nitti, M. P., Forgione, R. N., Marra, F. S., & Casamassima, F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.552429 · Cited by 12

The newer antipsychotics: underlying mechanisms and the new clinical realities

Kapur, S., Natesan, S., & Remington, G. J. (2004) · Current Opinion in Psychiatry · doi:10.1097/00001504-200403000-00008 · Cited by 12

Drug-Tea Polyphenol Interaction (III) Incompatibility between Aripiprazole Oral Solution and Green Tea

Ikeda, H., Yamanaka, M., Takahashi, S., Ohata, T., Yukawa, M., Nakashima, R., Tsutsumi, H., Fujisawa, M., & Aki, H. (2022) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c21-00746 · Cited by 11

Impact of N-Alkylamino Substituents on Serotonin Receptor (5-HTR) Affinity and Phosphodiesterase 10A (PDE10A) Inhibition of Isoindole-1,3-dione Derivatives

Czopek, A., Partyka, A., Bucki, A., Pawłowski, M., Kołaczkowski, M., Siwek, A., Głuch‐Lutwin, M., Koczurkiewicz, P., Pękala, E., Jaromin, A., et al. (2020) · Molecules · doi:10.3390/molecules25173868 · Cited by 12

The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials

Kane, J. M., Assunção-Talbott, S., Eudicone, J. M., Pikalov, A., Whitehead, R. E., & CRANDALL, D. T. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.06.018 · Cited by 11

Open labeled, randomized, switch-over study of two fixed doses (10/15mg) of aripiprazole : to evaluate its safety and efficacy in the treatment of Indian patients of schizophrenia.

Sarin, A., Nagpal, J., Bohra, N., Jiloha, R. C., Rao, G. P., Sharma, S. K., Vaishnav, M., Vaya, L., Karan, R. S., Patel, N. K., et al. (2004) · PubMed Central · Cited by 10

Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient

Patel, M., & Brunetti, L. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp090243 · Cited by 10

The substituted (S)-3-phenylpiperidine (−)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys

Brandt‐Christensen, M., Andersen, M. B., Fink‐Jensen, A., Werge, T. M., & Gerlach, J. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0297-1 · Cited by 10

Aripiprazole improves social interaction in Taiwanese children with pervasive developmental disorder.

Huang, S.-C., Tsai, S., & Yang, H. (2010) · PubMed · Cited by 9

Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism

Eissa, N., Venkatachalam, K., Jayaprakash, P., Yuvaraju, P., Falkenstein, M., Stark, H., & Sadek, B. S. (2022) · Pharmaceuticals · doi:10.3390/ph15080929 · Cited by 8

Aripiprazole combined with nerve growth factor improves cognitive function in mice with schizophrenia model

Lu, C., Li, S., Kang, L., Li, Q., Chen, H., Lin, Y., Zhang, H., Tang, Z., Bai, M., & Xiong, P. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137410 · Cited by 8

An Open-Label Trial of Aripiprazole Treatment in Dual Diagnosis Individuals: Safety and Efficacy

McRae‐Clark, A. L., Verduin, M. L., Tolliver, B. K., Carter, R. E., Wahlquist, A. E., Brady, K. T., Cluver, J. S., & Anderson, S. (2009) · Journal of Dual Diagnosis · doi:10.1080/15504260802620210 · Cited by 8

ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder

Noel, J. M., & Jackson, C. W. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa303 · Cited by 8

Antipsychotics

Vardanyan, R., & Hruby, V. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-411492-0.00006-7 · Cited by 7

Aripiprazole as a new treatment for the prolonged nocturnal sleep of patient with idiopathic hypersomnia

Imanishi, A., Omori, Y., Ishido, H., Sagawa, Y., Han, G., Mishima, K., Kanbayashi, T., & Kondo, H. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13290 · Cited by 7

Aripiprazole

Cada, D. J., Levien, T. L., & Baker, D. E. (2003) · Hospital Pharmacy · doi:10.1177/001857870303800308 · Cited by 7

Aripiprazole: Does Partial Dopaminergic Agonism Translate into Clinical Benefits?

Crismon, M. L., DeLeon, A., & Miller, A. L. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d014 · Cited by 7

Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review

Santorelli, M., Miuli, A., Pettorruso, M., Carlo, F. D., Berardis, D. D., Sensi, S. L., Martinotti, G., Clerici, M., & Giannantonio, M. D. (2024) · Current Neuropharmacology · doi:10.2174/1570159x23666241023115252 · Cited by 6

Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities

Brahm, N. C., McElwain, D. L., & Brown, R. C. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060209 · Cited by 6

Prospective clinical intervention study of aripiprazole and risperidone in the management of postoperative delirium in elderly patients after cardiovascular surgery

Sugawara, H., Koyama, A., Maruyama, T., Koda, Y., Fukunaga, H., Ishikawa, T., Takebayashi, M., Okamoto, K., Fukui, T., & Hashimoto, M. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13446 · Cited by 5

Methylphenidate-Induced Neuroleptic Malignant Syndrome

Basil, B., Mathews, M., & Budur, K. (2006) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v08n0109a · Cited by 5

Aripiprazole-induced parkinsonism

Sharma, A., & Sorrell, J. H. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000185025.40656.30 · Cited by 33

Search for novel antipsychotic drugs: dopamine forever?

Gyertyán, I. (2009) · BMC Pharmacology · doi:10.1186/1471-2210-9-s2-a52

A Failed New Antipsychotic Drug

Dubovsky, S. L. (2004) · Journal watch · doi:10.1056/jp200405200000009

Psychopharmacology

Iwata, K. (2014) · Oxford University Press eBooks · doi:10.1093/oso/9780199665662.003.0015

Chapter 25 Antipsychotic drugs

Colasanti, B. K. (2000) · Principles of medical biology · doi:10.1016/s1569-2582(00)80027-6 · Cited by 4